Several large-scale trials focused on sodium-glucose cotransporter-2 (SGLT2) inhibitors (SGLT2i) have reported favorable effects on the primary endpoint, a composite of myocardial infarction, stroke, and cardiovascular death of people who have type 2 diabetes [8, 9]. Here, SLC5A2 is linked to stroke disorder.